Accessibility Menu
 
GH Research logo

GH Research

(NASDAQ) GHRS

Current Price$20.53
Market Cap$1.33B
Since IPO (2021)+12%
5 YearN/A
1 Year+136%
1 Month+54%

GH Research Financials at a Glance

Market Cap

$1.33B

Revenue (TTM)

$0.00

Net Income (TTM)

$48.26M

EPS (TTM)

$-0.79

P/E Ratio

-27.22

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$20.53

Volume

8,530

Open

$21.88

Previous Close

$20.53

Daily Range

$20.43 - $22.25

52-Week Range

$8.75 - $24.66

GHRS News

GHRS: Motley Fool Moneyball Superscore

32

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GH Research

Industry

Pharmaceuticals

Employees

73

CEO

Villy Valcheva, MD

Headquarters

Dublin, D02 NX43, IE

GHRS Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-21%

Return on Capital

-22%

Return on Assets

-17%

Earnings Yield

-3.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.33B

Shares Outstanding

62.03M

Volume

8.53K

Short Interest

0.00%

Avg. Volume

212.10K

Financials (TTM)

Gross Profit

$335.00K

Operating Income

$60.68M

EBITDA

$60.34M

Operating Cash Flow

$43.55M

Capital Expenditure

$121.00K

Free Cash Flow

$43.67M

Cash & ST Invst.

$280.71M

Total Debt

$512.00K

GH Research Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$88.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.33B

N/A

Market Cap/Employee

$26.67M

N/A

Employees

50

N/A

Net Income

$14.14M

-60.6%

EBITDA

$16.61M

-90.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$280.20M

+88.4%

Accounts Receivable

$1.29M

-25.2%

Inventory

$0.00

N/A

Long Term Debt

$147.00K

-60.2%

Short Term Debt

$365.00K

+43.1%

Return on Assets

-16.74%

N/A

Return on Invested Capital

-21.68%

N/A

Free Cash Flow

$12.27M

-17.2%

Operating Cash Flow

$12.26M

-17.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBTXNanobiotix S.A.
$30.80-3.48%
PVLAPalvella Therapeutics, Inc.
$130.65+1.02%
SVRASavara Inc.
$5.28-5.88%
ABUSArbutus Biopharma Corporation
$4.43-3.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$57.40-0.01%
ONDSOndas
$10.87+0.01%
OPENOpendoor Technologies
$5.45+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.87-0.03%

Questions About GHRS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.